OSR subsidiary Woori IO signs NDA with Sinopharm to explore China opportunities

Reuters03-19

OSR subsidiary Woori IO signs NDA with Sinopharm to explore China opportunities

Woori IO, a subsidiary of OSR Holdings, signed a mutual NDA with Sinopharm Group Beijing Huahong to exchange confidential information on Woori IO’s near-infrared glucose monitoring technology.
The NDA framework covers evaluation of potential regulatory, clinical and commercial pathways in China.
Sinopharm Group reported 2024 revenue of about USD 81 billion.
China’s diabetes device market is projected to exceed USD 12 billion by 2032, according to Research and Markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603190855ACCESSWRNAPR_____1149235) on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620022385?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 20:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620022385","market":"fut","top_or_hot":-1,"title":"OSR subsidiary Woori IO signs NDA with Sinopharm to explore China opportunities","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      OSR subsidiary Woori IO signs NDA with Sinopharm to explore China opportunities\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Woori IO, a subsidiary of <a href=\"https://laohu8.com/S/OSRH\">OSR Holdings</a>, signed a mutual NDA with Sinopharm Group Beijing Huahong to exchange confidential information on Woori IO’s near-infrared glucose monitoring technology.\n        </li>\n<li>\n          The NDA framework covers evaluation of potential regulatory, clinical and commercial pathways in China.\n        </li>\n<li>\n          Sinopharm Group reported 2024 revenue of about USD 81 billion.\n        </li>\n<li>\n          China’s diabetes device market is projected to exceed USD 12 billion by 2032, according to Research and Markets.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603190855ACCESSWRNAPR_____1149235) on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OSR subsidiary Woori IO signs NDA with Sinopharm to explore China opportunities</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOSR subsidiary Woori IO signs NDA with Sinopharm to explore China opportunities\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-19 20:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      OSR subsidiary Woori IO signs NDA with Sinopharm to explore China opportunities\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Woori IO, a subsidiary of <a href=\"https://laohu8.com/S/OSRH\">OSR Holdings</a>, signed a mutual NDA with Sinopharm Group Beijing Huahong to exchange confidential information on Woori IO’s near-infrared glucose monitoring technology.\n        </li>\n<li>\n          The NDA framework covers evaluation of potential regulatory, clinical and commercial pathways in China.\n        </li>\n<li>\n          Sinopharm Group reported 2024 revenue of about USD 81 billion.\n        </li>\n<li>\n          China’s diabetes device market is projected to exceed USD 12 billion by 2032, according to Research and Markets.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603190855ACCESSWRNAPR_____1149235) on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1197","symbol_name":"保健护理产品经销商","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLbb7krB:1","article_id":"2620022385","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620022385","pubTimestamp":1773924915,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Woori IO, a subsidiary of OSR Holdings, signed a mutual NDA with Sinopharm Group Beijing Huahong to exchange confidential information on Woori IO’s near-infrared glucose monitoring technology.The NDA framework covers evaluation of potential regulatory, clinical and commercial pathways in China.Sinopharm Group reported 2024 revenue of about USD 81 billion.China’s diabetes device market is projected to exceed USD 12 billion by 2032, according to Research and Markets.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1197":"保健护理产品经销商","OSRH":"OSR Holdings","LU0640798160.USD":"EASTSPRING INVESTMENTS GLOBAL EMERGING MARKET DYNAMIC \"A\" (USD) ACC","BK1515":"抗疫概念","BK1500":"做空集合股","BK4139":"生物科技","LU1115378108.SGD":"Eastspring Investments - Global Emerging Markets Dynamic AS SGD","01099":"国药控股"},"translate_title":"OSR子公司友利IO与国药控股签署NDA探索中国机遇","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSRH":0.9,"01099":0.9},"content_text":"OSR subsidiary Woori IO signs NDA with Sinopharm to explore China opportunities\n    \n\n\n          Woori IO, a subsidiary of OSR Holdings, signed a mutual NDA with Sinopharm Group Beijing Huahong to exchange confidential information on Woori IO’s near-infrared glucose monitoring technology.\n        \n\n          The NDA framework covers evaluation of potential regulatory, clinical and commercial pathways in China.\n        \n\n          Sinopharm Group reported 2024 revenue of about USD 81 billion.\n        \n\n          China’s diabetes device market is projected to exceed USD 12 billion by 2032, according to Research and Markets.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603190855ACCESSWRNAPR_____1149235) on March 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620022385","isCrawlerRequest":true}